Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045".
Int J Cancer
; 154(4): 764-765, 2024 Feb 15.
Article
en En
| MEDLINE
| ID: mdl-37907776
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
Límite:
Female
/
Humans
Idioma:
En
Revista:
Int J Cancer
Año:
2024
Tipo del documento:
Article